The "Chemotherapy Induced Diarrhea - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

This "Chemotherapy-induced Diarrhea (CID) - Epidemiology Forecast - 2032" report delivers an in-depth understanding of the CID, historical and forecasted epidemiology as well as the CID market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Chemotherapy-induced Diarrhea (CID) Understanding

This Chemotherapy-induced diarrhea (CID) market report gives a thorough understanding of the disease.

Chemotherapy-induced diarrhea (CID), also called chemotherapy-related diarrhea, can be associated with various chemotherapy agents but is most commonly described with fluoropyrimidines (particularly fluorouracil [FU] and capecitabine) and irinotecan. Diarrhea is the dose-limiting and major toxicity of regimens containing a fluoropyrimidine with irinotecan.

However, in addition to conventional cytotoxic drugs, many molecularly targeted agents (including tyrosine kinase inhibitors [TKIs] and monoclonal antibodies) are also associated with CID. The occurrence of diarrhea affects the benefits of chemotherapy by reducing the dose or delaying the schedule and decreasing patients' quality of life; it can even increase the life-threatening risk of dehydration. Despite the severity of CID, it is often not recognized by clinicians and is poorly managed.

The severity is often described using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grades. Severity is determined by the number of stools per day or increased ostomy output compared with baseline, the need for hospitalization, and the effect on self-care activities. It is critical to ascertain the patient's baseline bowel pattern when grading the severity of CID. Although important, this grading system has limitations as it does not include either volume and duration or subjective complaints such as abdominal cramps and does not consider the patient's perception of the severity of this symptom.

Classification of CID uses grades established by the National Cancer Institute (NCI) to describe the severity of diarrhea. Grade 1 is an increase of fewer than four stools a day. Grade 2 is an increase of four to six stools a day. Grade 3 includes an increase of seven or more stools a day, an inability to control bowel movements, and a reduced ability to care for daily needs. Treating Grade 3 diarrhea usually requires a hospital stay. Grade 4 diarrhea is a life-threatening condition that requires immediate medical care.

Patients with mild-to-moderate (Grade 1 or 2) diarrhea and no moderate-to-severe abdominal cramping, Grade 2 or worse nausea/vomiting), decreased performance status, fever, frank bleeding, or suspected dehydration are classified as "uncomplicated." Additionally, patients who present with Grade 3 or 4 diarrhea and those with Grade 1 or 2 diarrhea associated with moderate-to-severe abdominal cramping, Grade 2 or worse nausea/vomiting, declining performance status, fever, sepsis, neutropenia, frank bleeding, or dehydration are classified as "complicated."

The diagnosis of CID starts with the doctor taking the patient's medical history, including exposure to possible causative agents. A careful physical examination may follow this to assess for signs of volume depletion (e.g., reduced skin turgor, hypotension, which may be primarily orthostatic, and low jugular venous pressure) and infection. Other than this, as per the patient's condition, various diagnostic tests may also be used to understand the patient's condition further. These tests include laboratory (stool cultures, blood cultures, etc.) and radiological exams (computed tomography [CT], endoscopy, ultrasound, etc.) in more compromised patients, microbiological examinations, etc.

Chemotherapy-induced Diarrhea (CID) Epidemiology

Chemotherapy-induced diarrhea (CID) epidemiology division provides insights into the historical and current CID patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed patient pool, their trends, and assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides a historical and forecasted CID epidemiology scenario in the 7MM covering the United States, EU4 and the United Kingdom, and Japan from 2019 to 2032.

The disease epidemiology covered in the report provides historical as well as forecasted chemotherapy-induced diarrhea epidemiology (segmented as incident cases of selected cancer types, total patients on chemotherapies by cancer type, incident cases of CID by selected cancer* types, grade-specific incident cases of CID, and total treated cases of CID) in the 7MM covering the United States, EU4 and the United Kingdom, and Japan from 2019 to 2032.

*Selected cancers include: colorectal cancer, breast cancer, bladder cancer, cervical cancer, esophageal cancer, head and neck, lung cancer, ovarian cancer, pancreatic cancer, testicular cancer, stomach cancer, endometrial cancer, castration-resistant prostate cancer (CRPC)

In 2022, the total incident cases of CID were around 1,000,000 in the 7MM, which is expected to rise by 2032 at a significant CAGR. In the 7MM, the highest number of total incident cases of CID were observed in the US, with a significant market share in the total cases.

Country Wise Chemotherapy-induced Diarrhea (CID) Epidemiology

The epidemiology segment also provides Chemotherapy-induced Diarrhea (CID) epidemiology data and findings across the United States, EU4 and the UK, and Japan.

As per The estimates, among the selected 13 major indications, lung cancer contributed to the highest number of CID cases in the US. The incidence cases of CID associated with lung cancer in the US were nearly 100,000 in 2022, projected to increase by 2032, with a significant CAGR. Apart from these, the incidence cases of CID associated with various cancers, including colorectal cancer, breast cancer, bladder cancer, cervical cancer, esophageal cancer, head and neck, ovarian cancer, pancreatic cancer, testicular cancer, stomach cancer, endometrial cancer, and CRPC were approximately 60,000, 80,000, 25,000, 3,500, 6,000, 25,000, 8,000, 10,000, 2,000, 10,000, 6,000, and 17,000, respectively in 2022. In 2022, the total number of incident cases of CID by selected cancer was ~360,000 cases in the US, which might rise by 2032.

Similarly, among the selected 13 major indications, lung cancer contributed to the highest number of CID cases in EU4 and the UK. The incident cases of CID by lung cancer in EU4 and the UK were nearly 100,000 in 2022, projected to rise by 2032, with a significant CAGR. Apart from these, the incidence cases of CID by colorectal cancer, breast cancer, bladder cancer, cervical cancer, esophageal cancer, head and neck, ovarian cancer, pancreatic cancer, testicular cancer, stomach cancer, endometrial cancer, and CRPC were approximately 95,000, 85,000, 35,000, 4,000, 9,000, 30,000, 10,000, 15,000, 3,000, 20,000, 5,000, and 16,000 in 2022, respectively. In 2022, the total number of incident cases of CID by selected cancer was ~430,000 cases in EU4 and the UK, which might rise by 2032.

Among selected 13 major indications, colorectal cancer contributed to the highest number of CID cases in Japan. The incident cases of CID by colorectal cancer in Japan were nearly 60,000 in 2022, projected to rise by 2032, with a moderate CAGR. Apart from these, the incidence cases of CID by lung cancer, breast cancer, bladder cancer, cervical cancer, esophageal cancer, head and neck, ovarian cancer, pancreatic cancer, testicular cancer, stomach cancer, endometrial cancer, and CRPC were approximately 60,000, 35,000, 12,000, 3,000, 8,000, 8,000, 4,000, 8,000, 200, 55,000, 2,000, and 4,000 in 2022, respectively. In 2022, the total number of incident cases of CID by selected cancer was ~250,000 cases in Japan, which might rise by 2032.

Scope of the Report

• The report covers a descriptive overview of Chemotherapy-induced diarrhea (CID), explaining its causes, symptoms, and pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 and the United Kingdom, and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of pain.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Incident cases of selected cancer types, Total patients on chemotherapies by cancer type, Incident cases of CID by selected cancer types, Grade-specific incident cases of CID, and Total treated cases of CID in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence chemotherapy-induced diarrhea (CID) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for CID.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chemotherapy-induced Diarrhea (CID) Report Key Strengths

• 10 Years forecast
• The 7MM coverage
• Incident cases of selected cancer types
• Total patients on chemotherapies by cancer type
• Incident cases of CID by selected cancer types
• Grade-specific incident cases of CID
• Total treated cases of CID

Key Questions Answered

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Chemotherapy-induced diarrhea (CID)?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 and the United Kingdom, and Japan?
• What is the historical CID patient pool in seven major markets covering the United States, EU4 and the United Kingdom, and Japan?
• What would be the forecasted patient pool of CID in seven major markets covering the United States, EU4 and the United Kingdom, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population of CID?
• Out of all the 7MM countries, which country would have the highest incident population of CID during the forecast period (2019-2032)?
• At what CAGR is the patient population expected to grow in the 7MM during the forecast period (2019-2032)?

For more information about this report visit https://www.researchandmarkets.com/r/p8d998

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230324005175/en/